Skip to content
MedsAcross

Medicine

Zylet 5 mg/3 mg per mL ophthalmic suspension

Loteprednol etabonate and Tobramycin · Ophthalmic · Bausch & Lomb
Available on requestPrescription onlyUS FDA

Zylet 5 mg/3 mg per mL ophthalmic suspension is a prescription medicine containing Loteprednol etabonate and Tobramycin for ophthalmic use, marketed by Bausch & Lomb, with its source record on the US FDA register. It is available on request for export supply from India to licensed hospitals, importers and physicians.

Availability

Available on request

Export supply from India to licensed buyers

Typical lead time

On request

Counted from payment and complete documents

Shipping

Ambient

PROTECT FROM FREEZING. Store upright at 15ºC to 25ºC (59ºF to 77ºF).

Key facts

Active ingredient (INN)
Loteprednol etabonate and Tobramycin
Brand
Zylet
Strength
5 mg/3 mg per mL
Dosage form
Ophthalmic suspension
Route
Ophthalmic
Packs
1 bottle
Marketing authorisation holder
Bausch & Lomb
Manufacturer
Bausch & Lomb
Origin register
US FDA, United States
Storage
PROTECT FROM FREEZING. Store upright at 15ºC to 25ºC (59ºF to 77ºF).
Cold chain
Not required on record
Prescription status
Prescription only
Controlled substance
Not recorded as controlled
HS code (indicative)
3004.32Indicative only. Your customs broker confirms the final tariff code.
Marketing category
marketed
Marketed since
14 December 2004
Identifiers
RxCUI 545255, 545259DailyMed set ID 3dd9b060-5355-404d-bdf1-09ee8b52a9f5NDC 24208-358Application NDA050804

Record updated 12 November 2026

Documents available

Documents that can be provided with this medicine. Your regulator may ask for more, and the quote lists the full set.

No document list is recorded for this medicine yet. Tell us which documents your regulator needs (for example a CoA, COPP or GMP certificate) when you request a quote.

Packs

PackCodeLabelerMarketed since
1 bottle, dropper in 1 carton / 5 mL in 1 bottle, dropper24208-358-05Bausch & Lomb14 December 2004
1 bottle, dropper in 1 carton / 10 mL in 1 bottle, dropper24208-358-10Bausch & Lomb14 December 2004

Status by register

Where this medicine is registered, from the source record and the regulator data we hold. Ask us about a country that is not listed.

RegisterStatusSource
US FDAListed, marketedSource record for this pageChecked 12 November 2026
US FDAFirst approved 14 December 2004Drugs@FDA
EU (EMA)Not recorded—
India (CDSCO)Not yet confirmed against CDSCO approval lists—
United StatesRegisteredUS FDA (NDC directory, openFDA)Checked 12 November 2026

Import route

Pick the destination country to see the legal import route, who applies and typical timelines, from our import guide for that country.

Import guides are available for 25 countries. Pick one to see its route summary.

BrazilColombiaEgyptEthiopiaGhanaIraqKazakhstanKenyaAll import guides

Alternatives

Other makers and brands of Loteprednol etabonate and Tobramycin 5 mg/3 mg per mL ophthalmic suspension.

Compare 1

Other strengths and forms of Loteprednol etabonate and Tobramycin

Clinical summary

Loteprednol etabonate and Tobramycin is a fixed-dose combination of an aminoglycoside antibacterial and a corticosteroid indicated and where superficial bacterial ocular infection or a risk of bacterial ocular infection exists, among other approved uses. MedsAcross supplies Loteprednol etabonate and Tobramycin for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.

Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review

Read about Loteprednol etabonate and Tobramycin

For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.

Data sources

Need Zylet 5 mg/3 mg per mL ophthalmic suspension for your hospital or patient?

Send one request with the destination country and quantity. We confirm availability, lead time and the documents your regulator needs.